Compare INTZ & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTZ | SCYX |
|---|---|---|
| Founded | 1983 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 26.3M |
| IPO Year | 2020 | 2014 |
| Metric | INTZ | SCYX |
|---|---|---|
| Price | $1.20 | $0.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.25 | $3.00 |
| AVG Volume (30 Days) | 109.7K | ★ 403.0K |
| Earning Date | 11-11-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,290,000.00 | $2,932,000.00 |
| Revenue This Year | $35.44 | $167.73 |
| Revenue Next Year | $23.57 | $290.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.49 | N/A |
| 52 Week Low | $0.71 | $0.57 |
| 52 Week High | $5.20 | $1.49 |
| Indicator | INTZ | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 40.23 | 51.18 |
| Support Level | $1.14 | $0.58 |
| Resistance Level | $1.36 | $0.64 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 22.86 | 80.03 |
Intrusion Inc is a cybersecurity company based in Plano, Texas. The group offers customers to access its threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol (IP) addresses. The company's product consists of On-Premise Network Protection, Cyber Threat Consulting, Cloud Network Security, and Endpoint Protection. Its solutions are INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. Its end-user customers include the U.S. federal government, state and local government entities, large and diversified conglomerates, and manufacturing entities.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.